FL-ETT
9.7.2024 20:26:35 CEST | Business Wire | Press release
ETT | iByond™, together with WorldVuer established WorldVuer iByond’s joint venture to develop the world’s first artificial intelligence operating system, WiOS (WorldVuer iByond Operating System). This collaboration is poised to modernize the technology estates of global enterprises, multinationals, sovereigns, and governments, leveraging intelligent interoperability, speed of innovation, AI, and an airtight security platform. “WiOS is poised to be one of the next big players to dominate the world stage alongside Android and iOS,” concluded Mr. Michael Sutton, Chief Media Officer of WorldVuer Inc.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240709427149/en/
Dr. Kenneth Ekow Andam, CEO of WorldVuer Inc. & Christopher Condon, Chairman & CEO of ETT | iByond™ (Photo: Business Wire)
ETT | iByond™, renowned for its cutting-edge Intelligent Interoperability AI platform, offers seamless integration and intelligent solutions tailored to enhance business operations across various industries. With a commitment to driving technological advancement, iByond's platform empowers organizations to harness the power of AI, enabling smarter decision-making, improved efficiency, and significant cost savings for enterprises. The iByond platform will serve individual consumers with WorldVuers’ technology products. WorldVuer brings to this venture their existing ecosystem of customers, consisting of 25 countries and 98 Million households, estimated to bring this partnership USD $6 Billion+ in annual software subscription revenues. Additionally, WorldVuer has a diverse portfolio of seven pioneering technologies, each designed to push the boundaries of innovation. WorldVuer’s products are built with an emphasis on security, incorporating airtight cybersecurity measures to ensure the utmost protection for users.
“We are excited to partner with WorldVuer, a company that shares our vision of innovation and excellence,” said Christopher Condon, Chairman and CEO of ETT | iByond™. “This partnership will enable us to deliver an unparalleled AI operating system with the highest level of speed, security, and data connection helping governments and enterprises worldwide to thrive in an increasingly digital world.”
“Innovating an AI Operating System that is built to transition the current global interconnected cloud devices within our communities and countries into an efficient, corroborative, and dynamic Interoperable platform to power current and futuristic devices makes this initiative an exciting opportunity for both WorldVuer and ETT | iByond™,” commented by Dr. Kenneth Ekow Andam, CEO of WorldVuer Inc.
“As we continue to witness extensive adoption and investment in AI across the enterprise and consumer markets globally, the WorldVuer iByond operating system provides breakthrough innovation and value by integrating hardware, software, and platform technologies and services. speed, security, and scale are now in reach at a level far beyond the data management and AI solutions currently available.” Lanny Cohen, Vice-Chairman & CPO, ETT | iByond™
About WorldVuer iByond
At WorldVuer | iByond, a joint venture that provides cutting-edge intelligent technologies powered by the iByond | WiOS system, focused on Enhanced Security, Seamless Data Integration, Improved Data Governance, and Enhanced Collaboration. WorldVuer iByond provides top-tier data protection, smooth data flow, regulatory compliance, and efficient communication, empowering organizations to boost productivity, creativity, and competitiveness. For more information, visit www.worldvueribyond.com
About ETT | iByond™
ETT | iByond™ is a leading provider of transformative solutions for enterprises, specializing in software, infrastructure, and innovations. iByond empowers businesses to embrace digital transformation and unlock new avenues for growth and success in today’s rapidly evolving business environment connecting humanity through intelligent data. For more information, visit www.ettworld.com
About WorldVuer
Leaders in interactive content development. We build products to bring a lifestyle narrative and communications capabilities into your home and office. Buy WorldVuer products and join our new emerging media empowering solutions that help you build success for you and your family. For more information, visit www.wvistore.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240709427149/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom